Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$23.58 - $30.91 $1.06 Million - $1.39 Million
-45,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $900,000 - $1.45 Million
45,000 New
45,000 $1.43 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Resolute Capital Asset Partners LLC Portfolio

Follow Resolute Capital Asset Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resolute Capital Asset Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Resolute Capital Asset Partners LLC with notifications on news.